Research programme: janus kinase inhibitors - Rigel Pharmaceuticals/Aclaris Therapeutics

Drug Profile

Research programme: janus kinase inhibitors - Rigel Pharmaceuticals/Aclaris Therapeutics

Alternative Names: R 333; R 548; R 723

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Aclaris Therapeutics; Rigel Pharmaceuticals
  • Class Skin disorder therapies
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alopecia areata
  • Discontinued Haematological malignancies

Most Recent Events

  • 23 Mar 2016 Aclaris Therapeutics has patent protection for Janus Kinase inhibitor in the Us and outside the US (Aclaris Therapeutics 10-K; March 2016)
  • 23 Mar 2016 Aclaris Therapeutics has patents pending for Janus kinase inhibitors in the US and outside the US (Aclaris Tehrapeutics 10-K; March 2016)
  • 07 Jan 2016 Preclinical trials in Alopecia areata in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top